With
the largest pharma company accounting for no more than 2%
of total biomedical research and internal pipelines largely
insufficient to sustain historical growth, external sources
of corporate growth acceleration including the licensing and
acquisition of brands, technologies and corporate entities
remains a high priority. The challenge for senior pharma executives
is accessing a stream of transactions on terms that are net
accretive in the face of rising competition and asset prices.
Infusion's
strengths in both strategy and corporate development are uniquely
suited to this challenge. Infusion's value-driven approach
to corporate development emphasizes the identification of
strategic transactions with the potential to generate unique
and superior partner value. Our goal: Create opportunities
with the potential for outsized returns while avoiding value-exhausting
bidding contests. |
